Russell Mumper, PhD
Russ Mumper is vice dean of the UNC Eshelman School of Pharmacy and the John A. McNeill Distinguished Professor in the Division of Molecular Pharmaceutics. He was also the first director of the Center for Nanotechnology in Drug Delivery at the University of North Carolina at Chapel Hill and served in this role from 2007-2012.
From 1999 to 2007, Mumper was a faculty member in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Kentucky. He served as vice chair of the department from 2004 to 2007. Also, from 1999 to 2006, Mumper was the associate director of the Center for Pharmaceutical Science & Technology. Prior to becoming a for-profit company in 2007, the CPST was a unique, university-based, fully-integrated, FDA-registered GMP pharmaceutical manufacturing facility. Mumper led the CPST’s efforts to complete full product development resulting in the successful submission of seven different INDs and commencement of human clinical trials with both industrial and university partners.
After completing a postdoctoral fellowship in the Center for Bioengineering at the University of Washington in 1992, Mumper held various product development positions in the pharmaceutical/biotech industry working for Burroughs-Wellcome Co. in North Carolina and GeneMedicine Inc. and Virotex Corporation, both in The Woodlands, Texas. Since returning to academia in 1999, Mumper has received more than $10.2 million in research grants/contracts as principal investigator (and over $28.6 million total). Mumper has more than 295 scientific publications/abstracts and forty-five patents or patents pending.
In 2006, he received the AAPS Lipid-Based Drug Delivery Award sponsored by Gattefossé Corporation and the American Association of Pharmaceutical Scientists (AAPS).
In 2007, Mumper was recognized by the University of Kentucky Alumni Association as one of six “Great Teachers” at UK. This award is the oldest, continuously given award for teaching on UK’s campus.
In 2009, he was elected Fellow of the AAPS.
In 2013, he received the Distinguished Teaching Award for Post-Baccalaureate Instruction, a campus-wide award at UNC-Chapel Hill.
Mumper serves on the editorial board of three pharmaceutical journals and is an ad-hoc member of several scientific review panels for the National Institutes of Health. He continues to serve as a consultant to the industry and as an expert patent witness. Mumper was the chair of the Bio-Targeting Working Group of the NCI Alliance for Nanotechnology in Cancer from 2010-2012 and is currently a member of the steering committee of the AAPS Nanotechnology Focus Group.
Mumper has cofounded five companies including NanoMed Pharmaceuticals Inc., Four Tigers LLC and Berryceuticals LLC (both based in Paris and Lexington, Kentucky), Capture Pharmaceuticals LLC (based in Chapel Hill, North Carolina), and IonX Capital Holdings Inc. (based in Lexington, Kentucky).
Mumper’s research program is focused primarily in five areas.
- Nanotemplate engineering of nano-based detection devices and cell-specific nanoparticles for tumor and dendritic cell targeting and vaccines. Current projects relate to using nanotechnology to target and overcome multi-drug resistant cancer, and as vaccine delivery systems for HIV proteins and adjuvants
- Biocompatibility, hemocompatibility, and toxicology of nanoparticles and nanomaterials
- Antibody-drug conjugates
- Mucoadhesive gels, thin-films, and intravaginal rings for (trans)mucosal delivery of drugs, vaccines, and microbicides
- Anticancer and anti-inflammatory properties of berries and berry extracts